Navigation Links
Boehringer Ingelheim Expands Investigation of Interferon-free Hepatitis C Treatment Regimens to Reach More Patient Types through Presidio Pharmaceuticals Clinical Collaboration
Date:9/10/2013

p>Boehringer Ingelheim has a comprehensive interferon-free clinical trial program, HCVerso®, which includes three pivotal Phase 3 studies. The HCVerso® studies aim to enroll approximately 1,100 treatment-naive and experienced HCV genotype-1b (GT-1b) patients, including those who are interferon eligible or ineligible, and those with compensated liver cirrhosis.

For more information regarding the trial, please visit www.clinicaltrials.gov.

About Boehringer Ingelheim in Hepatitis C Virus (HCV)
In partnership with the scientific community, our clinical trial program is rigorously designed to find answers to the challenges that HCV patients face, including those who are the most difficult to treat. Our pivotal HCV clinical trials for faldaprevir and deleobuvir are comprised of two multi-trial programs, STARTVerso® and HCVerso®.

Faldaprevir, also known as BI 201335, is an investigational, oral protease inhibitor that is specifically designed to target viral replication in the liver. Boehringer Ingelheim is developing faldaprevir as a core component of both interferon-based and interferon-free hepatitis C treatment regimens. STARTVerso®1 is the first of an ongoing multi-study Phase 3 trial program that is evaluating faldaprevir combined with PegIFN/RBV. Three additional trials in treatment-naive, treatment-experienced and HIV co-infected patients with chronic genotype-1 HCV are near clinical completion. Deleobuvir, also known as BI 207127, is an investigational NS5B non-nucleoside polymerase inhibitor that has shown the potential to eliminate interferon from HCV treatment when combined in a regimen with faldaprevir and RBV. Phase 2 trials of this interferon-free regimen have been completed and Phase 3 HCVerso® trials investigating this regimen are now underway. As part of our long-term commitment to HCV, the company is exploring other combinations o
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Boehringer Ingelheim Pharmaceuticals, Inc. Statement on RE-ALIGN Data
2. Boehringer Ingelheim Announces Agreement to Study Real-World Use of Oral Anticoagulants
3. Boehringer Ingelheim Renews and Expands License to NextBio Research Platform
4. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies
5. Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference
6. Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
7. ASCO 2013: Boehringer Ingelheim to Present Data Across Multiple Cancers, Including Different Treatment Settings for Advanced NSCLC
8. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
9. Boehringer Ingelheim to Announce Pivotal Phase 3 Hepatitis C Data at the International Liver Congress
10. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
11. Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 2015  Delays in the launch and execution ... the decision-making process, resulting in missed opportunities and ... biopharmaceutical companies to develop a tactical approach to ... and more meaningful insights. According ... three-quarters of benchmarked study participants use review cycle ...
(Date:8/28/2015)... , Aug. 28, 2015 ... has announced the addition of the "Investigation ... to their offering. Originally discovered by ... Yoshitomi Pharmaceutical Industries, Ltd) as an inflammatory drug, ... Senju Pharmaceutical Co., Ltd under the trade name ...
(Date:8/28/2015)... , Aug. 28, 2015 ... addition of the "Investigation Report on China,s Tobramycin ... Tobramycin is a traditional antibiotic whose eye drop and ... treatment of potential infection or inflammation caused by eye ... are able to produce tobramycin, among which ...
Breaking Medicine Technology:Expediting the Pharmaceutical Market Research Process for Faster Insights 2Investigation Report on China's Pranoprofen Market, 2010-2019 2Investigation Report on China's Tobramycin Market, 2015-2019 2
... N.Y., Oct. 25, 2011 Misonix, Inc. (NASDAQ: ... that designs, manufactures and markets innovative therapeutic ultrasonic ... surgery, neurosurgery, laparoscopic surgery, and other surgical and ... the BoneScalpel™ Ultrasonic Bone Cutting System at the ...
... HIGHLIGHTS:2011 Results (all percentages are to comparable periods in 2010) ... to $626 million. Q3 sales grew organically by 4% with ... 4% and 2%, respectively.  Recently completed acquisitions contributed an additional ... additional 5% to reported sales growth in Q3. ...
Cached Medicine Technology:Misonix Exhibits BoneScalpel™ at the International Meeting on Advanced Spine Techniques 2Misonix Exhibits BoneScalpel™ at the International Meeting on Advanced Spine Techniques 3Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 2Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 3Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 4Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 5Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 6Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 7Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 8Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 9Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 10Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 11Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 12Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 13
(Date:8/28/2015)... , ... August 28, 2015 , ... ... or those who might personally be struggling with chemical dependency, may be able ... Best Drug Rehabilitation, a results-driven holistic treatment center for addiction located in Western ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... Library for documenting and diagramming network and data center assets and audio-video devices, ... Device Model, Cisco Nexus 5000 Series, HP ProLiant Gen9, EMC VNX Series , ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Nashville ... military veterans leading in business. Mr. Troy Mizell, Chairman of the Board ... Nashville Business Journal's 2015 Veterans Awards will recognize Nashville military veterans who, through ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... loyalty at a low cost. Personalized with practice contact information and logos, Calendars ... Dental offices can also incorporate Calendars into seasonal mailings, thank you and welcome ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... Mendon, IL, ... of good music and good people, all for a good cause. In its second ... 2015, sponsored once more by Best Drug Rehabilitation. The “Mission” of “Music With A ...
Breaking Medicine News(10 mins):Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 2Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 3Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 2Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 3Health News:MyGenetx Board Member Receives Veterans Award 2Health News:SmartPractice® Introduces 2016 Calendars for Dental Practice Giveaways 2Health News:Best Drug Rehabilitation Sponsors "Music With A Mission" Concert Featuring Avenue Beat 2
... ... One online magazine and website, www.usariseup.com , provides a forum to have an ... ... the heated debates raging over immigration, America,s multi-racial, multi-ethinic society is still the foundation ...
... for suspected pulmonary embolism test negative, researchers find , TUESDAY, ... necessary in many patients suspected of having a blood clot ... identify those most likely to require the procedure, a new ... clot, usually from the leg, moves through the bloodstream and ...
... ... Medical Genetics to meet virtual repository technology needs of the network, , ... Reston, VA (PRWEB) June 15, ... American College of Medical Genetics (ACMG) has selected the company to contribute web-based applications ...
... ... “Learn More” series , ... NY (PRWEB) June 15, 2010 -- VoIP Supply, North America’s leading supplier of Voice over ... Buyers Guide . The VoIP Phone Buyers Guide is the second guide to be released ...
... ... York-based tutoring , testing and coaching center Brain Academy has once again helped a ... learning. Brain Academy,s unique focus on cognitive improvement is not only academically effective, but ... subjects. , ...
... ... Enthusiastically Embrace Any Innovation That Enables Them To Fit The Care Of Their Parents Into ... ... person over the age of 65 will need some form of long term care during ...
Cached Medicine News:Health News:Why A Multi-Racial, Multi-Ethnic Society Needs Open and Sustained Dialogue 2Health News:Why A Multi-Racial, Multi-Ethnic Society Needs Open and Sustained Dialogue 3Health News:Docs Should Assess Lung Clot Risk Before Ordering Scan 2Health News:Technology Innovation Advances Newborn Screen Translational Research Network 2Health News:Technology Innovation Advances Newborn Screen Translational Research Network 3Health News:VoIP Supply Releases VoIP Phone Buyers Guide 2Health News:Brain Academy's Revolutionary New Approach to Tutoring and Test Prep Helps Students Find Academic Success 2Health News:Brain Academy's Revolutionary New Approach to Tutoring and Test Prep Helps Students Find Academic Success 3Health News:Brain Academy's Revolutionary New Approach to Tutoring and Test Prep Helps Students Find Academic Success 4Health News:Brain Academy's Revolutionary New Approach to Tutoring and Test Prep Helps Students Find Academic Success 5Health News:Online Services Will Energise The Country's Invisible Healthcare Service 2Health News:Online Services Will Energise The Country's Invisible Healthcare Service 3
... RNA Mini Kit allows purification ... cell-free fluid samples. Examples of ... be isolated with this kit ... to, RNA from hepatitis A, ...
The Mago® Plus Automated EIA Analyzer is a fully automated, integrated ELISA system. Together, with immunosimplicity® reagents, the Mago® Plus provides a flexible, integrated solution ...
... computer-enhanced microplate reader with a ... flexible and rapid photometric analysis. ... and reliable photometric measurement of ... shaking before reading) and can ...
The Rapidpoint 400/405 instrument is a point-of-care blood gas analyzer that's fast, easy to operate and reliable....
Medicine Products: